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Spinocerebellar ataxias (SCAs) are dominantly inherited progressive 
ataxia disorders that can lead to premature death. We aimed to study the 
overall survival of the most common spinocerebellar ataxias: SCA1, SCA2, 
SCA3, and SCA6. We also aimed to identify the strongest contributing 
predictors that influence overall survival. 
Methods:  
In this longitudinal cohort study (EUROSCA), we enrolled men and women, 
aged 18 years or older, with positive genetic test results for SCA1, 
SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias from 
17 ataxia referral centers in ten European countries. Survival was 
defined as the time from enrollment to death for any reason. We used the 
Cox regression model adjusted for age at baseline to analyze survival. We 
used prognostic factors with P < 0*05 from multivariate model to build 
nomograms and assessed their performance based on discrimination and 
calibration. This study is registered with ClinicalTrials.gov, number 
NCT02440763. 
Findings:  
Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1, SCA2, 
SCA3, or SCA6 were enrolled and followed. The 10-year survival rate was 
57% (95 %CI: 47 - 69) for SCA1, 74% (67 - 81) for SCA2, 73% (65 - 82) for 
SCA3, and 87% (80 - 94) for SCA6. Factors associated with shorter 
survival were dysphagia (HR: 4*52 [95%CI=1*83 - 11*15]) and a higher 
value for the scale for the assessment and rating of ataxia (SARA) score 
(1*26 [1*19 - 1*33]) for SCA1; older age at inclusion (1*04 [1*01 - 
1*08]), longer CAG repeat number (1*16 [1*03 - 1*31]), and higher SARA 
score (1*15 [1*10 - 1*20]) for SCA2; older age at inclusion (1*44 [1*20 - 
1*74]), dystonia (2*65 [1*21 - 5*53]), higher SARA score (1*26 [1*17 - 
1*35]), and negative interaction between CAG and age at inclusion (0*994 
[0*991 - 0*997]) for SCA3; and higher SARA score (1*17 [1*08 - 1*27]) for 
SCA6. The nomogram-predicted probability of 10-year survival showed good 
discrimination (c-index equal to 0*905 ± 0*027, 0*822 ± 0*032, 0*891 ± 
0*021 and 0*825 ± 0*054 for SCA1, 2, 3, and 6, respectively) and 
excellent calibration: in each genotype, the predicted probability of 
five- and 10-year survival was very close to the actual observed 
survival.  
Interpretation:  
Our study provides quantitative data on the survival of the most common 
spinocerebellar ataxias based on a follow-up period that exceeds those of 
the previous studies. These results have substantial implications for the 
design of future interventional studies of SCA; the prognostic survival 
nomogram would be useful for patient selection and stratification but 
need validation in external population.  
Funding:  
EU FP6 (EUROSCA, grant LSHM-CT-503304), German Ministry of Education and 
Research (GeneMove), Polish Ministry of Scientific Research and 
Information Technology, EU FP7 (Neuromics, grant F5-2012-305121), and 
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Spinocerebellar ataxias (SCAs) are dominantly inherited progressive ataxia disorders that can lead to premature death. 
We aimed to study the overall survival of the most common spinocerebellar ataxias: SCA1, SCA2, SCA3, and SCA6. 
We also aimed to identify the strongest contributing predictors that influence overall survival. 
Methods:  
In this longitudinal cohort study (EUROSCA), we enrolled men and women, aged 18 years or older, with positive 
genetic test results for SCA1, SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias from 17 ataxia 
referral centers in ten European countries. Survival was defined as the time from enrollment to death for any reason. We 
used the Cox regression model adjusted for age at baseline to analyze survival. We used prognostic factors with P < 
0·05 from multivariate model to build nomograms and assessed their performance based on discrimination and 
calibration. This study is registered with ClinicalTrials.gov, number NCT02440763. 
Findings:  
Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1, SCA2, SCA3, or SCA6 were enrolled and followed. 
The 10-year survival rate was 57% (95 %CI: 47 – 69) for SCA1, 74% (67 – 81) for SCA2, 73% (65 – 82) for SCA3, 
and 87% (80 – 94) for SCA6. Factors associated with shorter survival were dysphagia (HR: 4·52 [95%CI=1·83 – 
11·15]) and a higher value for the scale for the assessment and rating of ataxia (SARA) score (1·26 [1·19 – 1·33]) for 
SCA1; older age at inclusion (1·04 [1·01 – 1·08]), longer CAG repeat number (1·16 [1·03 – 1·31]), and higher SARA 
score (1·15 [1·10 – 1·20]) for SCA2; older age at inclusion (1·44 [1·20 – 1·74]), dystonia (2·65 [1·21 – 5·53]), higher 
SARA score (1·26 [1·17 – 1·35]), and negative interaction between CAG and age at inclusion (0·994 [0·991 – 0·997]) 
for SCA3; and higher SARA score (1·17 [1·08 – 1·27]) for SCA6. The nomogram-predicted probability of 10-year 
survival showed good discrimination (c-index equal to 0·905 ± 0·027, 0·822 ± 0·032, 0·891 ± 0·021 and 0·825 ± 0·054 
for SCA1, 2, 3, and 6, respectively) and excellent calibration: in each genotype, the predicted probability of five- and 
10-year survival was very close to the actual observed survival.  
Interpretation:  
Our study provides quantitative data on the survival of the most common spinocerebellar ataxias based on a follow-up 
period that exceeds those of the previous studies. These results have substantial implications for the design of future 
interventional studies of SCA; the prognostic survival nomogram would be useful for patient selection and stratification 
but need validation in external population.  
Funding:  
EU FP6 (EUROSCA, grant LSHM-CT-503304), German Ministry of Education and Research (GeneMove), Polish 
Ministry of Scientific Research and Information Technology, EU FP7 (Neuromics, grant F5-2012-305121), and 





Panel: Research in context 
Evidence before this study 
We searched PubMed using the search terms [“spinocerebellar ataxia” OR “dominant ataxia” OR “Machado-Joseph 
disease” AND “survival”] for reports published before October 31, 2017. Only peer-reviewed, English-language reports 
of studies performed in patients were considered. Four studies were identified: two were restricted to a single genotype 
(SCA2 and SCA3), the third focused on index cases with known SCA mutations and affected parents of SCA and 
analyzed SCAs due to polyglutamine expansion as a group, and the last was an international retrospective study with 
short follow-up. These studies were very heterogeneous in terms of design, population follow-up, and methods. Few 
predictors of death were identified: gender, year of birth, age at onset and repeat lengths of the expanded allele.  
Added value of this study 
In this European, multicenter, longitudinal study (EUROSCA) we prospectively investigated a large cohort of patients 
with SCA1, SCA2, SCA3, and SCA6 for 10 years. Survival rates differed with respect to genotype. A higher SARA 
score at baseline was associated with shorter survival for all genotypes. Nomograms constructed from these data 
allowed precise prediction of survival on an individual basis.  
Implications of all available evidence 
The available data provide quantitative information on overall survival of patients with SCA1, SCA2, SCA3, and 
SCA6, and allowed the identification of predictors of survival. The prognostic nomograms will help researchers to 
optimize the design of future clinical trials and need validation in external population to assist clinicians in counseling 





Spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of dominantly inherited autosomal 
progressive ataxia disorders. Several genetically distinct SCAs have been defined, the most common being SCA1, 
SCA2, SCA3, and SCA6. They are caused by translated CAG repeat expansions that code for elongated polyglutamine 
tracts within the various proteins associated with each type. In addition, there are SCAs caused by non-translated repeat 
expansions or conventional mutations. Clinically, they are characterized by progressive balance problems and 
incoordination, with onset most commonly during adulthood, that lead to severe disability and premature death.
1
 
Although life expectancy of SCA patients with these subtypes is substantially reduced, there are only a few studies that 
have estimated survival or identified factors that influence survival. Significantly decreased survival associated with 
CAG repeat number, age at onset, and year of birth was observed for Brazilian SCA3 patients.
2
 Similar findings were 
obtained for Cuban SCA2 patients, except for the effect of year of birth on survival.
3
 A recent study of 446 index cases 
with known SCA mutations and 509 affected relatives reported a lower age of death in patients with polyglutamine 
expansion than in those with other types of mutations.
4
 In addition, among the polyglutamine SCA cases, survival was 
significantly shorter for patients with SCA1 than those with SCA2, SCA3, SCA6, or SCA7.
4
  
The EUROSCA natural history study is a European multicenter longitudinal cohort study of patients with SCA1, SCA2, 
SCA3, and SCA6. It was initiated in 2005 with the goal of characterizing the natural history of the disease and 
identifying prognostic factors. We recorded phenotypical differences between genotypes at baseline and identiﬁed 




 years allowed us to establish 
genotype-speciﬁc progression rates and identify factors that determine the course of the disease. In this study, we report 
survival data of the EUROSCA participants based on an observational period of 10 years. The aim of this study was to 
(a) quantify overall survival of patients with SCA1, SCA2, SCA3, or SCA6, (b) identify prognostic factors that 
influence survival, and (c) develop a prognostic model that allows prediction of individual survival based on genetic 





Study design and population 
 
The study population consisted of 525 SCA patients recruited from the longitudinal multicenter (17 European centers) 
EUROSCA prospective cohort study
7
 between July 1, 2005 and Aug 31, 2006. Patients were identified with the help of 
an electronic patient registry that contained data for all patients with spinocerebellar ataxias who had been in contact 
with one of the study centers. These patients suffered from progressive, otherwise unexplained, ataxia and had a 
positive molecular genetic test for SCA1 (n = 117), SCA2 (n = 162), SCA3 (n = 139), or SCA6 (n = 107). Assessments 
were performed according to a written study protocol. Patients were seen at baseline and followed by annual visits for 
three years. Afterwards, study participants entered an extension phase in which study assessments were performed 
during routine visits, resulting in irregular intervals between the visits. The database was locked in November 03, 2016, 
after a maximum observation period of 11 years. The ethics committees of the participating centers approved the study. 
Written informed consent was obtained from all study participants at enrollment. 
Outcome and predictor variables 
 
The clinical outcome was overall survival. We updated the vital status available in the electronic EUROSCA patient 
registry to avoid survival bias. Thus, we retrieved the updated vital status from the electronic database when available, 
through interviews of family members, and by interrogation of records from civil registry offices when feasible. As 
candidate predictors we selected gender, age at onset and repeat lengths of the expended alleles which have been 
reported as predictors of death in previously published studies.
2-4
 As additional candidates, we selected disease duration, 
and factors that characterize the neurological phenotype (SARA, INAS, individual non-ataxia signs), mood (PHQ-9) 
and physical state (BMI, disease stage) of the study participants. “Any use of physiotherapy” was included, because it is 
the only known therapeutic intervention in ataxia. The complete list of candidate predictors is given in table 1 of the 
appendix. Demographical data included age, age at ataxia onset, gender, disease duration, disease stage at enrollment, 
and use of physiotherapy at any time. Body mass index (BMI) at baseline was calculated using the formula 
[weight/height
2
]. Scores on the scale for the assessment and rating of ataxia (SARA)
7
, total scores on the inventory of 
non-ataxia signs (INAS, 0-16), and individual non-ataxia signs, as given in the INAS, including reported abnormalities, 
such as dysphagia and double vision,
8
 were recorded at baseline. To assess the severity of depressive symptoms, the 
depression scale of the Patient Health Questionnaire (PHQ-9) was used. 
9
 The PHQ-9 is a 9-item self-rating 
questionnaire that simply scores each of the nine DSM-IV criteria for depressive disorders. The severity of depression is 
calculated by assigning scores of 0, 1, 2, and 3, to the response categories ”not at all”, ”several days”, “more than half 
the days” and “nearly every day” respectively. The sum score ranges from 0 (absence of depression) to 27 (severe 
depression). Repeat lengths of the expanded and normal alleles were determined at the Institute of Medical Genetics and 
Applied Genomics of the University of Tubingen (Tubingen, Germany).  
Data analysis 
 
Mean (standard deviation) or frequencies (percentages) were used to describe the continuous and categorical variables 
at baseline. Survival was calculated from the date of enrollment to death for any reason. Data for patients who were 
alive or lost to follow-up were censored. Time from enrollment was used as the time scale. Survival was estimated 
using the Kaplan-Meier method and compared using a log-rank test. Cox- proportional-hazard models adjusted for age 
at baseline were used to study prognostic factors, and then candidates with P <0.10 were entered in to the multivariate 
Cox regression. The strongest contributing predictors for death from multivariate regression were selected through 
backward procedure based on the lowest Akaike information criterion (AIC). Because the backward selection models 
heavily relies on statistical significance which in turn depends on statistical power, we computed a posteriori statistical 
power to highlight an increase in the risk of death of 2 (HR = 2) for any binary variable with a proportion of patient of 
50% in each group. Subsequent analyses were performed separately for each genotype, as survival differed between 
genotypes.  Assumptions of hazard proportionality and log-linearity were verified. 
A nomogram that included the selected prognostic factors was constructed from each final Cox model to estimate the 
probability of survival after five and 10 years. A raw prognostic score was computed by summing the contribution of 
each individual factor, based on the points given for each factor in the nomogram. We divided the patients of each 
genotype into three prognostic risk groups to provide a reasonable spread of risk. Thus, various cut-offs for the risk 
score were explored based on the optimal cut-off using the three-risk group approach.
9
 The distribution of 55%, 25%, 
and 20% for prognostic risk group 1 (good prognosis), 2 (intermediate prognosis), and 3 (poor prognosis), respectively, 
was used, as they were the most discriminative relative to the c-index (appendix). We performed calibration plots and 
computed the discrimination c-index to assess the performance of the nomograms. One thousand random samples of the 
population were used to derive the 95% confidence interval bootstrap percentile for the c-index. 
11,12
 The multivariate 
model was internally validated using the 1,000-samples bootstrap procedure.  
7 
 
All data analyses were performed using SAS version 9·4 (SAS institute) and the R package. Values of P < 0·05 were 
considered to be statistically significant and all tests were two-sided. 
Role of the funding source 
 
The sponsors of the study had no role in the design, data collection, data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all data in the study and had final responsibility for the decision to 




Between July 1, 2005, and Aug 31, 2006, we enrolled 525 patients with SCA1, SCA2, SCA3, or SCA6. Table 1 shows 
the clinical and demographical data. During the follow-up, 66 (13%) patients were lost to follow-up and 121 (23%) 
died: 36 (31%) with SCA1, 38 (24%) with SCA2, 34 (25%) with SCA3, and 13 (12 %) with SCA6. The causes of death 
were reported for 47% (57/121) of cases. Among them, pulmonary diseases (pneumonia or pulmonary insufficiency) 
were the most frequent (six in SCA1, four in SCA2, seven in SCA3, and one in SCA6), followed by unknown causes 
(three in SCA1, three in SCA2, six in SCA3, and two in SCA6), cardiac (five in SCA3 and three in SCA6), cancer (one 
in SCA1, two in SCA2, and three in SCA6), sepsis/cachexia (one in SCA1, one in SCA2, and two in SCA6), gastric 
(two in SCA2), suicide (one in SCA1 and one in SCA2), stroke (one in SCA2 and one in SCA3), and renal (one in 
SCA2). 
The five-year survival rate was 80% (95% CI: 72 – 88) for SCA1, 87% (95% CI: 82 – 93) for SCA2, 87% (95% CI: 82 
– 93) for SCA3, and 98% (95% CI: 95 – 100) for SCA6. The corresponding 10-year survival rate was 57% (95% CI: 47 
– 69), 74% (95% CI: 67 – 81), 73% (95% CI: 65 – 82), and 87% (95% CI: 80 – 94). Overall, survival was significantly 
different between SCAs (figure 1, p = 0·0002). The risk of death was higher for SCA1 (HR: 3·79, 95% CI: 2·01 – 
7·15), SCA2 (HR: 2·13, 95% CI: 1·13 – 4·00), and SCA3 (HR: 2·46, 95% CI: 1·30 – 4·66) than SCA6· Moreover, the 
risk of death for SCA1 was higher than that for SCA2 (HR: 1·80, 95% CI: 1·14 – 2·8) or SCA3 (HR: 1·63, 95% CI: 
1·02 – 2·61), whereas it was similar between SCA2 and SCA3 (HR: 0·91, 95% CI: 0·57 – 1·44).  
We applied univariate Cox regression modeling adjusted for age at baseline to identify predictors for death for each 
genotype. For SCA1, 19 of 28 evaluated predictors were associated with survival (appendix): CAG repeat number, age 
at onset, disease duration, BMI, disease stage, PHQ9 sum score, SARA score, number of non-ataxia signs, and the 
following individual non-ataxia signs: areflexia, paresis, muscle atrophy, fasciculation, myoclonus, chorea/dyskinesia, 
dystonia, resting tremor, urinary dysfunction, cognitive impairment and dysphagia (appendix). A predictive model 
obtained from the multivariate Cox analysis, adjusted on age at baseline identified two strongest contributing  risk 
factors for death (table 2): dysphagia (HR: 4·52, 95% CI: 1·83 – 11·15; p = 0·0011) and higher SARA score (HR: 1·26, 
95% CI: 1·19 – 1·33; p < 0·0001).  
For SCA2, the significant predictors in the univariate analysis were CAG repeat number, age at onset, disease duration, 
disease stage, SARA score, number of non-ataxia signs, and the following individual non-ataxia signs: paresis, muscle 
atrophy, fasciculation, myoclonus, rigidity, chorea/dyskinesia, dystonia and cognitive impairment (appendix). The 
strongest contributing risk factors for death (table 2) were older age at inclusion (HR: 1·04, 95% CI: 1·01 – 1·08; p = 
0·0130), longer CAG repeat number (HR: 1·16, 95% CI: 1·03 – 1·31; p = 0·0158), and higher SARA score (HR: 1·15, 
95% CI: 1·10 – 1·20; p < 0·0001).  
For SCA3, CAG repeat number, age at onset, disease duration, disease stage, PHQ9 sum score, SARA score, number of 
non-ataxia signs, and the following individual non-ataxia signs: extensor plantar signs, spasticity, paresis, muscle 
atrophy, fasciculation, rigidity, chorea/dyskinesia, dystonia  and brainstem oculomotor were significant predictors of 
death in the univariate analysis (appendix). The strongest contributing  risk factors (table 2) were older age at inclusion 
(HR: 1·44, 95% CI: 1·20 – 1·74; p = 0·0001), dystonia (HR: 2·65, 95% CI: 1·21 – 5·53; p = 0·0151), higher SARA 
score (HR: 1·26, 95% CI: 1·17 – 1·35; p < 0·0001), and a negative interaction between CAG repeat number and age at 
inclusion (HR: 0·994, 95% CI: 0·991 – 0·997;  p < 0·0001). Patients with CAG-expanded alleles with less than 62 
repeats had a higher risk of death for older age at inclusion, whereas those with more than 62 repeats had a higher risk 
of death for younger age at inclusion, independently of the severity of the disease. In addition, there was an age-
dependent effect on the risk of death associated with CAG-expanded alleles: the older the age at baseline, the weaker 
the effect of CAG-expanded alleles on the risk of death, and conversely, the younger the age at baseline, the stronger 
the effect. 
In SCA6, disease stage, SARA score and rigidity were significantly associated with survival in Cox univariate analyses, 
whereas urinary dysfunction (p = 0·06) and cognitive impairment (p = 0·07) were borderline (appendix). The only 
contributing risk factor for death was a higher SARA score (HR: 1·17, 95% CI: 1·08 – 1·27; p = 0·0001) (table 2).  
A posteriori statistical power to highlight an increase in the risk of death of 2 (HR = 2) for any binary variable with a 
proportion of patient of 50% in each group was 55%, 58%, 53% and 24% for SCA1, 2, 3 and 6 respectively. 
We built nomograms that included all selected factors from the final Cox models to predict the probability of five- and 
10-year survival for each genotype (appendix). The nomograms showed that the SARA score contributed the most 
strongly to the prognosis for SCA1, SCA2, and SCA6, whereas age at baseline and its interaction with CAG were the 
strongest factors for SCA3. The number of CAG repeats and age at baseline had a moderate impact on the survival of 
SCA2 patients, whereas dysphagia and dystonia had a low impact on the survival of SCA1 and SCA3 patients, 
9 
 
respectively. A raw score was computed from the nomograms, and the patients were classified into three risk categories: 
good, intermediate, and poor prognosis based on the thresholds defined in the appendix. For example, a 50-year-old 
SCA1 patient (3 points) with dysphagia (17 points) and a SARA score of 20 (50 points) has 70 points, placing him in 
the intermediate group with a probability of five and 10-year survival of 80% (95% CI 73 – 87) and 5% (95% CI 1 – 9), 
respectively (appendix). 
The prognostic nomograms had good discriminatory capacity for all SCAs (appendix). The adjusted nomograms c-
index for predicting death at 10 years was 0·905 ± 0·027, 0·822 ± 0·032 0·891 ± 0·021 and 0·825 ± 0·054 for SCA1, 2, 
3, and 6, respectively. Moreover, the Kaplan-Meier curves of the three stratification risk groups were clearly separated 
(figure 2). The calibration plots showed excellent agreement between the nomogram prediction and the actual predicted 
probability of five- and 10-year survival (appendix). The uncertainties measured by the bootstrapping procedure in the 
internal validation were close to the estimated HR, except for a slight deviation for the dysphagia parameter in SCA1 




This study provides data on the overall survival of patients suffering from SCA1, SCA2, SCA3, or SCA6, based on 10-
year longitudinal findings of the EUROSCA cohort. Strengths of our study include the large number of patients and the 
prospective design of the study. The 10-year observational period may appear to be short, given an estimated survival of 
SCA patients of 20 to 30 years after ataxia onset.
4,13
 However, the average disease duration of study participants at 
inclusion was 10 years. Thus, we followed the patients up to an average of 20 years after ataxia onset. The information 
on vital status in the study database was incomplete, because most of the deceased patients had not attended the study 
centers in the years before death. We therefore used alternative approaches, including interviews of family members 
and records from civil registry offices to update the information on vital status. This allowed us to recover 40% 
(49/121) of the deaths and reduced the bias due to censorship, which is one of the major sources of bias in survival 
analyses. The other possible sources of bias were the bias due to the omission of a balanced covariate and the missing of 
a covariate being a confounder.
13
 We were unable to consider all potential covariates in our model. For example, 
clinical signs other than those assessed by the used scales, imaging and biomarker data were not available.  
In survival analysis, there is an ongoing debate on the choice of the optimal time scale. In this study, we used time-on-
study rather than disease duration or chronological age as the time scale. Various simulation studies
14–16
 have shown the 
time-on-study time scale, adjusted for age at inclusion,  to be the best as it is the most robust against misspecification 
(small bias) and is more suitable than other time scales to measure predictive discrimination, such as the time-dependent 
Area Under the Curve (AUC). We compared the different time scales to choose the most appropriate for our data. Our 
empirical results agreed with the simulation studies in that the time-on-study was the best.  
 
Survival was shortest for SCA1, intermediate for SCA2 and SCA3, and longest for SCA6. These results corroborate the 
finding reported by Monin et al.
4
 that the age at death was lower in SCA1 than in other SCAs due to polyglutamine 
expansions. These findings characterize SCA1 as the disease with the least favorable prognosis among the 
polyglutamine SCAs. Correspondingly, two longitudinal studies found that the progression of ataxia severity in SCA1 
was faster than in SCA2, SCA3, or SCA6.
5,6,17
 The 10-year death rate of the SCA2 patients of our cohort (24%) was 
lower than that of a Cuban SCA2 cohort (29%). Similarly, the death rate for SCA3 (25%) was lower than that of a 
Brazilian cohort (35%). Possible reasons for these discrepancies are selection bias, genetic background, and differences 
between health care systems. 
We used Cox regression modelling to identify predictors for death in each genotype. For SCA1 patients, ataxia severity 
measured with SARA and the presence of dysphagia increased the risk of death. These findings are contrary to the 
results of an international retrospective study.
12
 However, this study used different time scales and did not include 
clinical findings in the statistical models. For SCA2, the risk of death increased with older age at inclusion, longer CAG 
repeat number, and severity of ataxia. Longer CAG repeats were similarly found to be a risk factor for death in a Cuban 
SCA2 cohort.
3
 We were unable to confirm the effect of being female on death that was reported in the international 
retrospective study.
12
 For SCA3, predictors of shorter survival identified by univariate Cox analysis, such as early age 
of onset and long CAG repeat length, overlapped with factors reported in the Brazilian SCA3 study.
2
 None of the 
previous studies reported predictors for the risk of death in SCA6 patients. We found that only the severity of ataxia at 
baseline affected survival. The finding that the severity of ataxia at baseline measured with SARA was a predictor of 
survival in all genotypes underlines the clinical relevance and predictive power of SARA. In our analysis, we failed to 





We do not exclude to have missed some risk factors due to lack of power. 
Nomograms are widely used prognostic tools in various fields of medicine. For example, there are nomograms that 
allow prediction of lymph node metastasis in cancer patients. These nomograms may assist physicians in decisions on 
surgical management.
 22–24
 More recently, a prognosis nomogram was developed to predict individual outcomes after 
antiepileptic drug withdrawal in people with epilepsy. 
25
One main limit of the nomogram is that it assumes that 
outcomes remain constant over time. Consequently, its accuracy becomes less good over time probably because of 
changes in natural history of the disease, early diagnosis detection and improvements in therapy. 
21
 We constructed 
nomograms for each genotype that allowed predicting individual survival with high precision based on a number of 
easily accessible factors identified in the Cox models. Nomograms were constructed in a rigorous methodological 
framework, including the choice of the candidate predictors and time scale.
16
 The nomograms had good discriminatory 
capacity, and there was excellent agreement between the nomogram prediction and actual survival. DR Cox proposed to 
use the following distribution: 27%, 49·5%, and 27%, when categorizing the prognostic score in three groups.
10 
This 
distribution was not appropriate for our data, as we had a large number of patients with good prognoses. We chose the 
distribution that optimized the separation of the Kaplan Meier curves and thus retained the distribution with the largest 
c-index (appendix). However, the nomograms need to be externally validated on independent samples including non-
11 
 
European patients to determine the generalizability of the model.
10,11
 They may be further improved by the 
incorporation of imaging data and biomarkers.   
Our data extend the knowledge of the biological characteristics of SCA1, SCA2, SCA3, and SCA6. The nomograms are 
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Table 1: Population characteristics at baseline 
      SCA1 SCA 2 SCA 3 SCA 6 
      (n=117) (n=162) (n=139) (n=107) 
Gender (n, %male) 
 
71 (61) 74 (46) 73 (53) 58 (54) 
Age (years) 
  
46·3 ± 12·2 46·4 ± 13·3 48·8 ± 11·8 65·0 ± 10·9 
Age at onset (years) 
 
36·7 ± 10·4 35·2 ± 12·5 37·0 ± 11·3 54·3 ± 10·6 
Disease duration (years) 
 
9·5 ± 5·7 11·1 ± 6·0 11·7 ± 6·0 10·7 ± 6·9 
Number of CAG repeats  
 
47·6 ± 5·6 39·4 ± 3·5 69·1 ± 4·6 22·5 ± 2·2 
BMI (kg/m
2
)  24·4 ± 4·1 25·1 ± 4·3 23·1 ± 4·0 25·7 ± 4·1 
SARA score 
 
15·6 ± 9·1 15·7 ± 8·0 15·1 ± 8·5 15·2 ± 6·8 
PHQ-9 sum score  6·7 ± 6·4 5·5 ± 4·9 6·9 ± 6·2 5·3 ± 5·4 
Any physiotherapy use (yes)  43 (37) 75 (46) 75 (54) 51 (48) 
Number of non-ataxia signs  
  
4·8 ± 2·2 4·2 ± 2·2 4·9 ± 2·6 1·9 ± 1·6 
Death (n, % yes)  36 (31) 38 (24) 34 (25) 13 (12) 
Median follow-up (years), 95% CI 9·9 (6·9 10·1) 10·2 (10·1 10·3) 10·2 (10·1 10·4) 10·2 (10·1 10·3) 
The categorical variable are shown as n (%), the continuous variables as mean (SD). SARA = Scale for the Assessment 




Table 2: Multivariate Cox model 
 
          
§
Max score in   Internal validation 
Parameters   HR 95 % CI p-value nomogram Median (IQR) BHR BCI HR 95 % 
SCA1 
        Age at baseline (years) 1.01 0.98    1.04 0.53021 6 46 (37  55) 1.003 0.975   1.033 
Dysphagia (yes) 4.52 1.83    11.15 0.00107 17 0 (1    1) 7.029 1.939   41.81 
SARA score 
 
1.26 1.19     1.33 <.0001 100 13.5 (8.5   20.5) 1.288 1.201    1.382 
SCA2 
        Age at baseline (years) 1.04 1.01   1.08 0.01300 51 47.5 (37   54) 1.045 1.009   1.082 
CAG (number repeats) 1.16 1.03    1.31 0.01580 53 39 (37   41) 1.172 1.028    1.337 
SARA score 
 
1.15 1.10    1.20 <.0001 100 14 (10   19.5) 1.155 1.103    1.210 
SCA3 
        Age at baseline (years) 1.44 1.20   1.74 0.0001 100 48 (40   56) 1.692 1.179   2.486 
Dystonia (yes) 2.65 1.21    5.53 0.0151 4 0 (0    0) 2.898 1.132    7.341 
SARA score 
 
1.26 1.17    1.35 <.0001 33 14 (10   20.5) 1.295 1.189    1.406 
CAG (number repeats) 1.04 0.89    1.21 0.6501 5 69 (66   72) 1.151 0.867    1.533 
Interaction Age*CAG 0.994 0.991  0.997 <.0001 86 3328 (2850    3776) 0.993 0.988    0.998 
SCA6 
        Age at baseline (years) 1.02 0.95   1.08 0.6426 14 67 (58   73) 1.018 0.947   1.096 
SARA score   1.17 1.08    1.27 0.0001 100 14 (10.5   19) 1.187 1.080     1.306 
HR: hazard ratio, CI: confidence interval, BHR: bootstrap hazard ratio, BCI: bootstrap confidence interval; 
§
Maximum 





Figure 1: Overall survival from enrollment according to genotype  









Figure 1: Prognostic nomograms to predict the probability of individual overall survival of patients with 
spinocerebellar ataxia type 1, 2, 3, and 6. 
Points are assigned to each risk factor by drawing a line upward from the corresponding value to the ‘Points’ line. The 
total sum point for the three factors is plotted on the ‘Total points’ line. A line is drawn down to read the corresponding 
predictions of the probability of five- and 10-year survival.  
For example, a 50-year-old SCA1 patient (3 points) with dysphagia (17 points) and a SARA score of 20 (50 points) has 
70 points (3 + 17 + 50), placing him in the intermediate group with a probability of five- (blue line) and 10-year (red 
line) survival of 80% and 5%, respectively. 
 
Figure 2: Calibration plots for predicting ataxia patient overall survival at each time point by genotype.  
 
The X-axis shows the nomogram predicted probability of survival. Patients were grouped by quartiles of predicted risk. 
The Y-axis is the actual probability of five- (blue) and 10-year (red) survival estimated by the Kaplan-Meier method. 
The solid line represents the values from the nomograms with their 95% CI. A plot along a 45-degree line (dotted line) 
would indicate a perfect calibration model in which the predicted probabilities are identical to the actual outcomes. 
 
Table 1: Univariate Cox model in SCAs of the 28 potential predictors of death 
Table 2: Various range and threshold prognostic score computed from nomograms 
Table 3: Discrimination measures and β estimates with their SE from the Cox model 
Table 4: Individual non-ataxia signs characteristics at baseline  
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Spinocerebellar ataxias (SCAs) are dominantly inherited progressive ataxia disorders that can lead to premature death. 
We aimed to study the overall survival of the most common spinocerebellar ataxias: SCA1, SCA2, SCA3, and SCA6. 
We also aimed to identify the strongest contributing predictors that influence overall survival. 
Methods:  
In this longitudinal cohort study (EUROSCA), we enrolled men and women, aged 18 years or older, with positive 
genetic test results for SCA1, SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias from 17 ataxia 
referral centers in ten European countries. Survival was defined as the time from enrollment to death for any reason. We 
used the Cox regression model adjusted for age at baseline to analyze survival. We used prognostic factors with P < 
0·05 from multivariate model to build nomograms and assessed their performance based on discrimination and 
calibration. This study is registered with ClinicalTrials.gov, number NCT02440763. 
Findings:  
Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1, SCA2, SCA3, or SCA6 were enrolled and followed. 
The 10-year survival rate was 57% (95 %CI: 47 – 69) for SCA1, 74% (67 – 81) for SCA2, 73% (65 – 82) for SCA3, 
and 87% (80 – 94) for SCA6. Factors associated with shorter survival were dysphagia (HR: 4·52 [95%CI=1·83 – 
11·15]) and a higher value for the scale for the assessment and rating of ataxia (SARA) score (1·26 [1·19 – 1·33]) for 
SCA1; older age at inclusion (1·04 [1·01 – 1·08]), longer CAG repeat number (1·16 [1·03 – 1·31]), and higher SARA 
score (1·15 [1·10 – 1·20]) for SCA2; older age at inclusion (1·44 [1·20 – 1·74]), dystonia (2·65 [1·21 – 5·53]), higher 
SARA score (1·26 [1·17 – 1·35]), and negative interaction between CAG and age at inclusion (0·994 [0·991 – 0·997]) 
for SCA3; and higher SARA score (1·17 [1·08 – 1·27]) for SCA6. The nomogram-predicted probability of 10-year 
survival showed good discrimination (c-index equal to 0·905 ± 0·027, 0·822 ± 0·032, 0·891 ± 0·021 and 0·825 ± 0·054 
for SCA1, 2, 3, and 6, respectively) and excellent calibration: in each genotype, the predicted probability of five- and 
10-year survival was very close to the actual observed survival.  
Interpretation:  
Our study provides quantitative data on the survival of the most common spinocerebellar ataxias based on a follow-up 
period that exceeds those of the previous studies. These results have substantial implications for the design of future 
interventional studies of SCA; the prognostic survival nomogram would be useful for patient selection and stratification 
but need validation in external population.  
Funding:  
EU FP6 (EUROSCA, grant LSHM-CT-503304), German Ministry of Education and Research (GeneMove), Polish 
Ministry of Scientific Research and Information Technology, EU FP7 (Neuromics, grant F5-2012-305121), and 





Panel: Research in context 
Evidence before this study 
We searched PubMed using the search terms [“spinocerebellar ataxia” OR “dominant ataxia” OR “Machado-Joseph 
disease” AND “survival”] for reports published before October 31, 2017. Only peer-reviewed, English-language reports 
of studies performed in patients were considered. Four studies were identified: two were restricted to a single genotype 
(SCA2 and SCA3), the third focused on index cases with known SCA mutations and affected parents of SCA and 
analyzed SCAs due to polyglutamine expansion as a group, and the last was an international retrospective study with 
short follow-up. These studies were very heterogeneous in terms of design, population follow-up, and methods. Few 
predictors of death were identified: gender, year of birth, age at onset and repeat lengths of the expanded allele.  
Added value of this study 
In this European, multicenter, longitudinal study (EUROSCA) we prospectively investigated a large cohort of patients 
with SCA1, SCA2, SCA3, and SCA6 for 10 years. Survival rates differed with respect to genotype. A higher SARA 
score at baseline was associated with shorter survival for all genotypes. Nomograms constructed from these data 
allowed precise prediction of survival on an individual basis.  
Implications of all available evidence 
The available data provide quantitative information on overall survival of patients with SCA1, SCA2, SCA3, and 
SCA6, and allowed the identification of predictors of survival. The prognostic nomograms will help researchers to 
optimize the design of future clinical trials and need validation in external population to assist clinicians in counseling 





Spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of dominantly inherited autosomal 
progressive ataxia disorders. Several genetically distinct SCAs have been defined, the most common being SCA1, 
SCA2, SCA3, and SCA6. They are caused by translated CAG repeat expansions that code for elongated polyglutamine 
tracts within the various proteins associated with each type. In addition, there are SCAs caused by non-translated repeat 
expansions or conventional mutations. Clinically, they are characterized by progressive balance problems and 
incoordination, with onset most commonly during adulthood, that lead to severe disability and premature death.
1
 
Although life expectancy of SCA patients with these subtypes is substantially reduced, there are only a few studies that 
have estimated survival or identified factors that influence survival. Significantly decreased survival associated with 
CAG repeat number, age at onset, and year of birth was observed for Brazilian SCA3 patients.
2
 Similar findings were 
obtained for Cuban SCA2 patients, except for the effect of year of birth on survival.
3
 A recent study of 446 index cases 
with known SCA mutations and 509 affected relatives reported a lower age of death in patients with polyglutamine 
expansion than in those with other types of mutations.
4
 In addition, among the polyglutamine SCA cases, survival was 
significantly shorter for patients with SCA1 than those with SCA2, SCA3, SCA6, or SCA7.
4
  
The EUROSCA natural history study is a European multicenter longitudinal cohort study of patients with SCA1, SCA2, 
SCA3, and SCA6. It was initiated in 2005 with the goal of characterizing the natural history of the disease and 
identifying prognostic factors. We recorded phenotypical differences between genotypes at baseline and identiﬁed 




 years allowed us to establish 
genotype-speciﬁc progression rates and identify factors that determine the course of the disease. In this study, we report 
survival data of the EUROSCA participants based on an observational period of 10 years. The aim of this study was to 
(a) quantify overall survival of patients with SCA1, SCA2, SCA3, or SCA6, (b) identify prognostic factors that 
influence survival, and (c) develop a prognostic model that allows prediction of individual survival based on genetic 





Study design and population 
 
The study population consisted of 525 SCA patients recruited from the longitudinal multicenter (17 European centers) 
EUROSCA prospective cohort study
7
 between July 1, 2005 and Aug 31, 2006. Patients were identified with the help of 
an electronic patient registry that contained data for all patients with spinocerebellar ataxias who had been in contact 
with one of the study centers. These patients suffered from progressive, otherwise unexplained, ataxia and had a 
positive molecular genetic test for SCA1 (n = 117), SCA2 (n = 162), SCA3 (n = 139), or SCA6 (n = 107). Assessments 
were performed according to a written study protocol. Patients were seen at baseline and followed by annual visits for 
three years. Afterwards, study participants entered an extension phase in which study assessments were performed 
during routine visits, resulting in irregular intervals between the visits. The database was locked in November 03, 2016, 
after a maximum observation period of 11 years. The ethics committees of the participating centers approved the study. 
Written informed consent was obtained from all study participants at enrollment. 
Outcome and predictor variables 
 
The clinical outcome was overall survival. We updated the vital status available in the electronic EUROSCA patient 
registry to avoid survival bias. Thus, we retrieved the updated vital status from the electronic database when available, 
through interviews of family members, and by interrogation of records from civil registry offices when feasible. As 
candidate predictors we selected gender, age at onset and repeat lengths of the expended alleles which have been 
reported as predictors of death in previously published studies.
2-4
 As additional candidates, we selected disease duration, 
and factors that characterize the neurological phenotype (SARA, INAS, individual non-ataxia signs), mood (PHQ-9) 
and physical state (BMI, disease stage) of the study participants. “Any use of physiotherapy” was included, because it is 
the only known therapeutic intervention in ataxia. The complete list of candidate predictors is given in table 1 of the 
appendixFrom previous studies  and available data from the EUROSCA cohort,
6
 28 candidates predictors for death 
were selected. Demographical data included age, age at ataxia onset, gender, disease duration, disease stage at 
enrollment, and use of physiotherapy at any time. Body mass index (BMI) at baseline was calculated using the formula 
[weight/height
2
]. Scores on the scale for the assessment and rating of ataxia (SARA)
7
, total scores on the inventory of 
non-ataxia signs (INAS, 0-16), and individual non-ataxia signs, as given in the INAS, including reported abnormalities, 
such as dysphagia and double vision,
8
 were recorded at baseline. To assess the severity of depressive symptoms, the 
depression scale of the Patient Health Questionnaire (PHQ-9) was used. 
9
 The PHQ-9 is a 9-item self-rating 
questionnaire that simply scores each of the nine DSM-IV criteria for depressive disorders. The severity of depression is 
calculated by assigning scores of 0, 1, 2, and 3, to the response categories ”not at all”, ”several days”, “more than half 
the days” and “nearly every day” respectively. The sum score ranges from 0 (absence of depression) to 27 (severe 
depression). Repeat lengths of the expanded and normal alleles were determined at the Institute of Medical Genetics and 
Applied Genomics of the University of Tubingen (Tubingen, Germany).  
Data analysis 
 
Mean (standard deviation) or frequencies (percentages) were used to describe the continuous and categorical variables 
at baseline. Survival was calculated from the date of enrollment to death for any reason. Data for patients who were 
alive or lost to follow-up were censored. Time from enrollment was used as the time scale. Survival was estimated 
using the Kaplan-Meier method and compared using a log-rank test. Cox- proportional-hazard models adjusted for age 
at baseline were used to study prognostic factors, and then candidates with P <0.10 were entered in to the multivariate 
Cox regression. The strongest contributing predictors for death from multivariate regression were selected through 
backward procedure based on the lowest Akaike information criterion (AIC). Because the backward selection models 
heavily relies on statistical significance which in turn depends on statistical power, we computed a posteriori statistical 
power to highlight an increase in the risk of death of 2 (HR = 2) for any binary variable with a proportion of patient of 
50% in each group. Subsequent analyses were performed separately for each genotype, as survival differed between 
genotypes.  Assumptions of hazard proportionality and log-linearity were verified. 
A nomogram that included the selected prognostic factors was constructed from each final Cox model to estimate the 
probability of survival after five and 10 years. A raw prognostic score was computed by summing the contribution of 
each individual factor, based on the points given for each factor in the nomogram. We divided the patients of each 
genotype into three prognostic risk groups to provide a reasonable spread of risk. Thus, various cut-offs for the risk 
score were explored based on the optimal cut-off using the three-risk group approach.
9
 The distribution of 55%, 25%, 
and 20% for prognostic risk group 1 (good prognosis), 2 (intermediate prognosis), and 3 (poor prognosis), respectively, 
was used, as they were the most discriminative relative to the c-index (appendix). We performed calibration plots and 
computed the discrimination c-index to assess the performance of the nomograms. One thousand random samples of the 
7 
 
population were used to derive the 95% confidence interval bootstrap percentile for the c-index. 
11,12
 The multivariate 
model was internally validated using the 1,000-samples bootstrap procedure.  
All data analyses were performed using SAS version 9·4 (SAS institute) and the R package. Values of P < 0·05 were 
considered to be statistically significant and all tests were two-sided. 
Role of the funding source 
 
The sponsors of the study had no role in the design, data collection, data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all data in the study and had final responsibility for the decision to 




Between July 1, 2005, and Aug 31, 2006, we enrolled 525 patients with SCA1, SCA2, SCA3, or SCA6. Table 1 shows 
the clinical and demographical data. During the follow-up, 66 (13%) patients were lost to follow-up and 121 (23%) 
died: 36 (31%) with SCA1, 38 (24%) with SCA2, 34 (25%) with SCA3, and 13 (12 %) with SCA6. The causes of death 
were reported for 47% (57/121) of cases. Among them, pulmonary diseases (pneumonia or pulmonary insufficiency) 
were the most frequent (six in SCA1, four in SCA2, seven in SCA3, and one in SCA6), followed by unknown causes 
(three in SCA1, three in SCA2, six in SCA3, and two in SCA6), cardiac (five in SCA3 and three in SCA6), cancer (one 
in SCA1, two in SCA2, and three in SCA6), sepsis/cachexia (one in SCA1, one in SCA2, and two in SCA6), gastric 
(two in SCA2), suicide (one in SCA1 and one in SCA2), stroke (one in SCA2 and one in SCA3), and renal (one in 
SCA2). 
The five-year survival rate was 80% (95% CI: 72 – 88) for SCA1, 87% (95% CI: 82 – 93) for SCA2, 87% (95% CI: 82 
– 93) for SCA3, and 98% (95% CI: 95 – 100) for SCA6. The corresponding 10-year survival rate was 57% (95% CI: 47 
– 69), 74% (95% CI: 67 – 81), 73% (95% CI: 65 – 82), and 87% (95% CI: 80 – 94). Overall, survival was significantly 
different between SCAs (figure 1, p = 0·0002). The risk of death was higher for SCA1 (HR: 3·79, 95% CI: 2·01 – 
7·15), SCA2 (HR: 2·13, 95% CI: 1·13 – 4·00), and SCA3 (HR: 2·46, 95% CI: 1·30 – 4·66) than SCA6· Moreover, the 
risk of death for SCA1 was higher than that for SCA2 (HR: 1·80, 95% CI: 1·14 – 2·8) or SCA3 (HR: 1·63, 95% CI: 
1·02 – 2·61), whereas it was similar between SCA2 and SCA3 (HR: 0·91, 95% CI: 0·57 – 1·44).  
We applied univariate Cox regression modeling adjusted for age at baseline to identify predictors for death for each 
genotype. For SCA1, 20 19 of 28 evaluated predictors were associated with survival (appendix): CAG repeat number, 
age at onset, disease duration, BMI, age at onset, disease progression, disease stage, PHQ9 sum score, SARA score, 
INAS countnumber of non-ataxia signs, and various the following individual non-ataxia signs: including areflexia, 
extensor plantar, paresis, muscle atrophy, fasciculation, myoclonus, chorea/dyskinesia, dystonia, resting tremor, urinary 
dysfunction, cognitive impairment and dysphagia (appendix). A predictive model obtained from the multivariate Cox 
analysis, adjusted on age at baseline identified two strongest contributing  risk factors for death (table 2): dysphagia 
(HR: 4·52, 95% CI: 1·83 – 11·15; p = 0·0011) and higher SARA score (HR: 1·26, 95% CI: 1·19 – 1·33; p < 0·0001).  
For SCA2, the significant predictors in the univariate analysis were CAG repeat number, age at onset, disease 
progressionduration, disease stage, SARA score, number of non-ataxia signsINAS count, and the following various 
individual non-ataxia signs especially pyramidal and peripheral motor symptoms: paresis, muscle atrophy, fasciculation, 
myoclonus, rigidity, chorea/dyskinesia, dystonia and cognitive impairment (appendix). The strongest contributing risk 
factors for death (table 2) were older age at inclusion (HR: 1·04, 95% CI: 1·01 – 1·08; p = 0·0130), longer CAG repeat 
number (HR: 1·16, 95% CI: 1·03 – 1·31; p = 0·0158), and higher SARA score (HR: 1·15, 95% CI: 1·10 – 1·20; p < 
0·0001).  
For SCA3, CAG repeat number, age at onset, disease progressionduration, disease stage, PHQ9 sum scoredepressive 
symptom, SARA score, number of non-ataxia signsINAS score, and the followingvarious individual non-ataxia signs: 
including extensor plantar signs, spasticity, paresis, muscle atrophy, fasciculation, rigidity, chorea/dyskinesia, dystonia ,  
and brainstem oculomotor and dysphagia were significant predictors of death in the univariate analysis (appendix). The 
strongest contributing  risk factors (table 2) were older age at inclusion (HR: 1·44, 95% CI: 1·20 – 1·74; p = 0·0001), 
dystonia (HR: 2·65, 95% CI: 1·21 – 5·53; p = 0·0151), higher SARA score (HR: 1·26, 95% CI: 1·17 – 1·35; p < 
0·0001), and a negative interaction between CAG repeat number and age at inclusion (HR: 0·994, 95% CI: 0·991 – 
0·997;  p < 0·0001). Patients with CAG-expanded alleles with less than 62 repeats had a higher risk of death for older 
age at inclusion, whereas those with more than 62 repeats had a higher risk of death for younger age at inclusion, 
independently of the severity of the disease. In addition, there was an age-dependent effect on the risk of death 
associated with CAG-expanded alleles: the older the age at baseline, the weaker the effect of CAG-expanded alleles on 
the risk of death, and conversely, the younger the age at baseline, the stronger the effect. 
In SCA6, disease stage, SARA score and rigidity were significantly associated with survival in Cox univariate analyses, 
whereas urinary dysfunction (p = 0·06) and cognitive impairment (p = 0·07) were borderline (appendix). The only 
contributing risk factor for death was a higher SARA score (HR: 1·17, 95% CI: 1·08 – 1·27; p = 0·0001) (table 2).  
A posteriori statistical power to highlight an increase in the risk of death of 2 (HR = 2) for any binary variable with a 
proportion of patient of 50% in each group was 55%, 58%, 53% and 24% for SCA1, 2, 3 and 6 respectively. 
We built nomograms that included all selected factors from the final Cox models to predict the probability of five- and 
10-year survival for each genotype (appendix). The nomograms showed that the SARA score contributed the most 
strongly to the prognosis for SCA1, SCA2, and SCA6, whereas age at baseline and its interaction with CAG were the 
strongest factors for SCA3. The number of CAG repeats and age at baseline had a moderate impact on the survival of 
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SCA2 patients, whereas dysphagia and dystonia had a low impact on the survival of SCA1 and SCA3 patients, 
respectively. A raw score was computed from the nomograms, and the patients were classified into three risk categories: 
good, intermediate, and poor prognosis based on the thresholds defined in the appendix. For example, a 50-year-old 
SCA1 patient (3 points) with dysphagia (17 points) and a SARA score of 20 (50 points) has 70 points, placing him in 
the intermediate group with a probability of five and 10-year survival of 80% (95% CI 73 – 87) and 5% (95% CI 1 – 9), 
respectively (appendix). 
The prognostic nomograms had good discriminatory capacity for all SCAs (appendix). The adjusted nomograms c-
index for predicting death at 10 years was 0·905 ± 0·027, 0·822 ± 0·032 0·891 ± 0·021 and 0·825 ± 0·054 for SCA1, 2, 
3, and 6, respectively. Moreover, the Kaplan-Meier curves of the three stratification risk groups were clearly separated 
(figure 2). The calibration plots showed excellent agreement between the nomogram prediction and the actual predicted 
probability of five- and 10-year survival (appendix). The uncertainties measured by the bootstrapping procedure in the 
internal validation were close to the estimated HR, except for a slight deviation for the dysphagia parameter in SCA1 




This study provides data on the overall survival of patients suffering from SCA1, SCA2, SCA3, or SCA6, based on 10-
year longitudinal findings of the EUROSCA cohort. Strengths of our study include the large number of patients and the 
prospective design of the study. The 10-year observational period may appear to be short, given an estimated survival of 
SCA patients of 20 to 30 years after ataxia onset.
4,13
 However, the average disease duration of study participants at 
inclusion was 10 years. Thus, we followed the patients up to an average of 20 years after ataxia onset. The information 
on vital status in the study database was incomplete, because most of the deceased patients had not attended the study 
centers in the years before death. We therefore used alternative approaches, including interviews of family members 
and records from civil registry offices to update the information on vital status. This allowed us to recover 40% 
(49/121) of the deaths and reduced the bias due to censorship, which is one of the major sources of bias in survival 
analyses. The other possible sources of bias were the bias due to the omission of a balanced covariate and the missing of 
a covariate being a confounder.
13
 We were unable to consider all potential covariates in our model. For example, 
clinical signs other than those assessed by the used scales, imaging and biomarker data were not availableThese are 
almost inevitable because we were unable to consider all potential covariates in our model. For example, painful muscle 
cramps, imaging and biomarker data were not available.  
In survival analysis, there is an ongoing debate on the choice of the optimal time scale. In this study, we used time-on-
study rather than disease duration or chronological age as the time scale. Various simulation studies
14–16
 have shown the 
time-on-study time scale, adjusted for age at inclusion,  to be the best as it is the most robust against misspecification 
(small bias) and is more suitable than other time scales to measure predictive discrimination, such as the time-dependent 
Area Under the Curve (AUC). We compared the different time scales to choose the most appropriate for our data. Our 
empirical results agreed with the simulation studies in that the time-on-study was the best.  
 
Survival was shortest for SCA1, intermediate for SCA2 and SCA3, and longest for SCA6. These results corroborate the 
finding reported by Monin et al.
4
 that the age at death was lower in SCA1 than in other SCAs due to polyglutamine 
expansions. These findings characterize SCA1 as the disease with the least favorable prognosis among the 
polyglutamine SCAs. Correspondingly, two longitudinal studies found that the progression of ataxia severity in SCA1 
was faster than in SCA2, SCA3, or SCA6.
5,6,17
 The 10-year death rate of the SCA2 patients of our cohort (24%) was 
lower than that of a Cuban SCA2 cohort (29%). Similarly, the death rate for SCA3 (25%) was lower than that of a 
Brazilian cohort (35%). Possible reasons for these discrepancies are selection bias, genetic background, and differences 
between health care systems. 
We used Cox regression modelling to identify predictors for death in each genotype. For SCA1 patients, ataxia severity 
measured with SARA and the presence of dysphagia increased the risk of death. These findings are contrary to the 
results of an international retrospective study.
12
 However, this study used different time scales and did not include 
clinical findings in the statistical models. For SCA2, the risk of death increased with older age at inclusion, longer CAG 
repeat number, and severity of ataxia. Longer CAG repeats were similarly found to be a risk factor for death in a Cuban 
SCA2 cohort.
3
 We were unable to confirm the effect of being female on death that was reported in the international 
retrospective study.
12
 For SCA3, predictors of shorter survival identified by univariate Cox analysis, such as early age 
of onset and long CAG repeat length, overlapped with factors reported in the Brazilian SCA3 study.
2
 None of the 
previous studies reported predictors for the risk of death in SCA6 patients. We found that only the severity of ataxia at 
baseline affected survival. The finding that the severity of ataxia at baseline measured with SARA was a predictor of 
survival in all genotypes underlines the clinical relevance and predictive power of SARA. In our analysis, we failed to 





We do not exclude to have missed some risk factors due to lack of power. 
Nomograms are widely used prognostic tools in various oncology and other fields of medicine. especially in all aspects 
of the care of patients
18
 including patient’s selection both in pre or postoperative phase.22–24 For example, there are 
nomograms that allow prediction of lymph node metastasis in cancer patients. These nomograms may assist physicians 
in decisions on surgical management.
 22–24
 More recently, a prognosis nomogram was developed to predict individual 
outcomes after antiepileptic drug withdrawal in people with epilepsy. 
25
One main limit of the nomogram is that it 
assumes that outcomes remain constant over time. Consequently, its accuracy becomes less good over time probably 
because of changes in natural history of the disease, early diagnosis detection and improvements in therapy. 
21
 We 
constructed nomograms for each genotype that allowed predicting individual survival with high precision based on a 
number of easily accessible factors identified in the Cox models. Nomograms were constructed in a rigorous 
methodological framework, including the choice of the candidate predictors and time scale.
16
 The nomograms had good 
discriminatory capacity, and there was excellent agreement between the nomogram prediction and actual survival. DR 
Cox proposed to use the following distribution: 27%, 49·5%, and 27%, when categorizing the prognostic score in three 
groups.
10 
This distribution was not appropriate for our data, as we had a large number of patients with good prognoses. 
11 
 
We chose the distribution that optimized the separation of the Kaplan Meier curves and thus retained the distribution 
with the largest c-index (appendix). However, the nomograms need to be externally validated on independent samples 
including non-European patients to determine the generalizability of the model.
10,11
 They may be further improved by 
the incorporation of imaging data and biomarkers.   
Our data extend the knowledge of the biological characteristics of SCA1, SCA2, SCA3, and SCA6. The nomograms are 
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Table 1: Population characteristics at baseline 
      SCA1 SCA 2 SCA 3 SCA 6 
      (n=117) (n=162) (n=139) (n=107) 
Gender (n, %male) 
 
71 (61) 74 (46) 73 (53) 58 (54) 
Age (years) 
  
46·3 ± 12·2 46·4 ± 13·3 48·8 ± 11·8 65·0 ± 10·9 
Age at onset (years) 
 
36·7 ± 10·4 35·2 ± 12·5 37·0 ± 11·3 54·3 ± 10·6 
Disease duration (years) 
 
9·5 ± 5·7 11·1 ± 6·0 11·7 ± 6·0 10·7 ± 6·9 
Number of CAG repeats  
 
47·6 ± 5·6 39·4 ± 3·5 69·1 ± 4·6 22·5 ± 2·2 
BMI (kg/m
2
)  24·4 ± 4·1 25·1 ± 4·3 23·1 ± 4·0 25·7 ± 4·1 
SARA score 
 
15·6 ± 9·1 15·7 ± 8·0 15·1 ± 8·5 15·2 ± 6·8 
PHQ-9 sum score  6·7 ± 6·4 5·5 ± 4·9 6·9 ± 6·2 5·3 ± 5·4 
Any physiotherapy use (yes)  43 (37) 75 (46) 75 (54) 51 (48) 
Number of non-ataxia signs  
  
4·8 ± 2·2 4·2 ± 2·2 4·9 ± 2·6 1·9 ± 1·6 
Death (n, % yes)  36 (31) 38 (24) 34 (25) 13 (12) 
Median follow-up (years), 95% CI 9·9 (6·9 10·1) 10·2 (10·1 10·3) 10·2 (10·1 10·4) 10·2 (10·1 10·3) 
The categorical variable are shown as n (%), the continuous variables as mean (SD). Data are shown as the mean (SD) 




Table 2: Multivariate Cox model 
  
   
§Max score in 
 
Internal validation 
Parameters HR 95% CI p-value nomogram *Range BCI HR 95% 
SCA1 
      
Age at baseline (years) 1·01 0·98   1·04 0·53021 6 18 - 76 0·975      1·033 
Dysphagia (yes) 4·52 1·83  11·15 0·00107 17 0 - 1 1·939     41·81 
SARA score  1·26 1·19  1·33 <·0001 100 2 - 40 1·201    1·382 
SCA2 
   
 
 
 Age at baseline years) 1·04 1·01  1·08 0·01300 51 18 - 84 1·009     1·082 
CAG (number of repeats) 1·16 1·03  1·31 0·01580 53 33 - 52 1·028     1·337 
SARA score 1·15 1·10  1·20 <·0001 100 2 - 39 1·103     1·210 
SCA3 
   
 
 
 Age at baseline (years) 1·44 1·20  1·74 0·0001 100 14 - 81 1·179     2·486 
Dystonia (yes) 2·65 1·21   5·53 0·0151 4 0 - 1 1·132     7·341 
SARA score 1·26 1·17   1·35 <·0001 33 1 - 40 1·189     1·406 
CAG 1·04 0·89   1·21 0·6501 5 56 - 91 0·867     1·533 
Interaction Age*CAG 0·994 0·991   0·997 <·0001 86 1200 – 4900 0·988   0·998 
SCA6 
   
 
 
 Age at baseline (years) 1·02 0·95  1·08 0·64260 14 37 - 85 0·947     1·096 
SARA score  1·17 1·08  1·27 0·0001 100 1 - 33 1·080     1·306 
*Range is the min and max of the corresponding covariate, HR: hazard ratio, CI: confidence interval, BCI: bootstrap 
confidence interval; 
§
Maximum number attributed by a nomogram for each predictor. 
          
§
Max score in   Internal validation 
Parameters   HR 95 % CI p-value nomogram Median (IQR) BHR BCI HR 95 % 
SCA1 
        Age at baseline (years) 1.01 0.98    1.04 0.53021 6 46 (37  55) 1.003 0.975   1.033 
Dysphagia (yes) 4.52 1.83    11.15 0.00107 17 0 (1    1) 7.029 1.939   41.81 
SARA score 
 
1.26 1.19     1.33 <.0001 100 13.5 (8.5   20.5) 1.288 1.201    1.382 
SCA2 
        Age at baseline (years) 1.04 1.01   1.08 0.01300 51 47.5 (37   54) 1.045 1.009   1.082 
CAG (number repeats) 1.16 1.03    1.31 0.01580 53 39 (37   41) 1.172 1.028    1.337 
SARA score 
 
1.15 1.10    1.20 <.0001 100 14 (10   19.5) 1.155 1.103    1.210 
SCA3 
        Age at baseline (years) 1.44 1.20   1.74 0.0001 100 48 (40   56) 1.692 1.179   2.486 





1.26 1.17    1.35 <.0001 33 14 (10   20.5) 1.295 1.189    1.406 
CAG (number repeats) 1.04 0.89    1.21 0.6501 5 69 (66   72) 1.151 0.867    1.533 
Interaction Age*CAG 0.994 0.991  0.997 <.0001 86 3328 (2850    3776) 0.993 0.988    0.998 
SCA6 
        Age at baseline (years) 1.02 0.95   1.08 0.6426 14 67 (58   73) 1.018 0.947   1.096 
SARA score   1.17 1.08    1.27 0.0001 100 14 (10.5   19) 1.187 1.080     1.306 
HR: hazard ratio, CI: confidence interval, BHR: bootstrap hazard ratio, BCI: bootstrap confidence interval; 
§
Maximum 





Figure 1: Overall survival from enrollment according to genotype  









Figure 1: Prognostic nomograms to predict the probability of individual overall survival of patients with 
spinocerebellar ataxia type 1, 2, 3, and 6. 
Points are assigned to each risk factor by drawing a line upward from the corresponding value to the ‘Points’ line. The 
total sum point for the three factors is plotted on the ‘Total points’ line. A line is drawn down to read the corresponding 
predictions of the probability of five- and 10-year survival.  
For example, a 50-year-old SCA1 patient (3 points) with dysphagia (17 points) and a SARA score of 20 (50 points) has 
70 points (3 + 17 + 50), placing him in the intermediate group with a probability of five- (blue line) and 10-year (red 
line) survival of 80% and 5%, respectively. 
 
Figure 2: Calibration plots for predicting ataxia patient overall survival at each time point by genotype.  
 
The X-axis shows the nomogram predicted probability of survival. Patients were grouped by quartiles of predicted risk. 
The Y-axis is the actual probability of five- (blue) and 10-year (red) survival estimated by the Kaplan-Meier method. 
The solid line represents the values from the nomograms with their 95% CI. A plot along a 45-degree line (dotted line) 
would indicate a perfect calibration model in which the predicted probabilities are identical to the actual outcomes. 
 
Table 1: Univariate Cox model in SCAs of the 28 potential predictors of death 
 
Table 2: Various range and threshold prognostic score computed from nomograms 
Table 3: Discrimination measures and β estimates with their SE from the Cox model 
Table 4: Individual non-ataxia signs characteristics at baseline  
 
Table 5: Predicted probability and actual observed survival of five- and 10-year 
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Title: Overall survival in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study 
 
Point by point answers to the comments of the editor and reviewer are given below. As requested, we have 
highlighted all modifications in a track mode in the manuscript and indicated the page (highlighted version of the 
manuscript with) in the letter. 
We are grateful to the editor for re-reviewing our paper. 





1. Please include the following in your revised paper: 
a. data to support the statement that calibration was excellent. 
 
To support the statement that calibration was excellent, we have added the following sentence in the Abstract 
section: “In each genotype, the predicted probability of five- and 10-year survival was very close to the actual 
observed survival”. In addition, we have added a table 5 including the predicted probability and actual observed 
survival (appendix). 
 
Table 5: Predicted probability and actual observed five- and 10-year survival 
 
    Time prediction  
  
5-year survival prediction 10-year survival prediction 
Genotype 
§
Groups Predicted Observed Predicted Observed 
SCA1 
     
 
1 0.306 0.302 0.000 0.000 
 
2 0.885 0.881 0.327 0.315 
 
3 0.980 1.000 0.831 0.867 
 
4 0.999 1.000 0.952 0.950 
SCA2 
     
 
1 0.640 0.630 0.351 0.335 
 
2 0.937 0.943 0.828 0.823 
 
3 0.909 0.918 0.816 0.832 
 
4 0.995 1.000 0.961 0.971 
SCA3 
     
 
1 0.584 0.577 0.167 0.144 
 
2 0.912 0.926 0.758 0.773 
 
3 0.991 1.000 0.933 0.966 
 
4 0.999 1.000 0.997 1.000 
SCA6 
     
 
1 0.909 0.910 0.700 0.682 
 
2 0.999 1.000 0.807 0.815 
 
3 0.999 1.000 0.934 0.955 
  4 0.998 1.000 0.990 1.000 
§
Participants of each genotype were grouped in quartiles based on the risk score from the respective multivariate 
model. 
In each genotype, the predicted probability of five- and 10-year survival was very close to the actual observed 
survival supporting the statement of a good calibration. 
 
*Reply to Reviewers Comments
 b. clarification in your introduction of the relation between spinocerebellar ataxias and CAG repeat expansions, 
for non-specialist readers. The first paragraph could be interpreted as suggesting that all SCA is caused by CAG 
repeat expansions, whereas the second paragraph could be interpreted as meaning that people with SCA can 
have other types of mutation instead. 
 
To clarify the relation between spinocerebellar ataxias and CAG repeat expansion, we have inserted the 
following sentence to the first para of the Introduction. 
 
“In addition, there are SCAs caused by non-translated repeat expansions or conventional mutations.”  
 
c. a little further clarification of how candidate predictors were selected from previous studies. Did you have 
some criteria for selection that could be mentioned? 
 
Gender, age at onset and repeat lengths of the expended alleles were predictors of death reported in previously 
published studies. As additional candidate predictors we selected disease duration, and factors that characterize 
the neurological phenotype (SARA, INAS, individual non-ataxia signs) and the physical state (BMI, disease 
stage) of the study participants. “Any use of physiotherapy” was included, because it is the only known 
therapeutic intervention in ataxia. PHQ-9 was added on request of one of the reviewers. 
To clarify how we selected the candidate predictors, we have replaced the sentence of the second paragraph of 
the Methods “From previous studies 2–4 and available data from the EUROSCA cohort,6 28 candidates predictors 
for death were selected” by the following sentence: “As candidate predictors we selected gender, age at onset 
and repeat lengths of the expended alleles which have been reported as predictors of death in previously 
published studies.
2-4
 As additional candidates, we selected disease duration, and factors that characterize the 
neurological phenotype (SARA, INAS, individual non-ataxia signs), mood (PHQ-9) and physical state (BMI, 
disease stage) of the study participants. “Any use of physiotherapy” was included, because it is the only known 
therapeutic intervention in ataxia. The complete list of candidate predictors is given in table 1 of the appendix”. 
 
d. a complete list of the predictors associated with survival in your main paper, if you have not already done so. I 
counted 20 predictors in the results third paragraph, but use of "including" suggests that the list is not complete. 
 
Following the first revision, the number of predictors was incorrect due to an error. There are 19 instead of 20 
predictors for death since the extensar plantar sign was not associated with the risk of death from the univariate 
Cox model in SCA1 (appendix and para 3 Results), 14 for SCA2 (appendix and para 4 Results), 16 instead of 17 
in SCA3 since dysphagia was not associated with risk of death (appendix and para 5 Results) and 3 for SCA6 
(appendix and para 6 Results).  
 
The list of predictors has thus been updated: we have modified the sentence by removing extensar plantar sign 
(para 3 of the Results) and dysphagia (para 5 of the Results) from the list of potential predictors of death in the 
main document. 
 
In paragraphs 3, 4 and 5, the word "including" has been deleted. 
 
e. clarification of what is meant by the new text in the first sentence of the discussion fifth paragraph. "especially 
in all aspects of the care of patients" suggests that nomograms are already widely used for all neurological 
diseases. By "other fields of medicine", do you mean fields other than oncology or other than neurology? It is 
also not immediately obvious what is meant by "patient's selection both in pre or postoperative phase". Could 
you please clarify selection for what - perhaps for surgery before it, but for what after surgery? 
 
We have reformulated the first sentence of the paragraph and added concrete examples of the use of nomograms 
in oncology and neurology. The beginning of the paragraph now reads, as follows: 
“Nomograms are widely used prognostic tools in various fields of medicine.18 For example, there are 
nomograms that allow prediction of lymph node metastasis in cancer patients. These nomograms may assist 
physicians in decisions on surgical management.
22–24
 More recently, a prognosis nomogram was developed to 
predict individual outcomes after antiepileptic drug withdrawal in people with epilepsy.
25” 
 
2. Could you please confirm (not necessarily in your paper) why PHQ9 has been added as a predictor in the 
latest revision but it was not included previously?
 
 
We have added PHQ9 upon the request of the reviewer 1(3rd question).  
  Could other relevant predictors have been similarly missed? 
 
This is possible since there may be completely unknown factors. Other factors that are likely to be relevant, such 
as imaging data, could not be considered because there were not available. This point is addressed in the last part 
of the first paragraph of the discussion: “We were unable to consider all potential covariates in our model. For 
example, clinical signs other than those assessed by the used scales, imaging and biomarker data were not 
available”. 
 
 And could you please confirm that it is correct that none of the data in your abstract or main paper seem to have 
changed in light of inclusion of this predictor? 
 
We confirm that the inclusion of PHQ-9 did not change the results from multivariate Cox mode and thus the 
conclusion from abstract and main paper. 
 
3. Figures, tables, panels, and appendices: 
a. please clarify in the legend of table 1 what is shown. For example, the current column headings suggest that 
the max score values should either be within or the upper limit of the range values in the next column, neither of 
which seems to be the case. Could the range values be replaced by median (IQR)? And do the 95% CI for the 
internal validation have corresponding HR values that could be included, or do they always apply to the same 
HR as given in the first column (in which case, could that be clarified)? 
 
The modifications have been performed as requested (Table 1 and 2).  
 
In the legend of Table 1, we have replaced “Data” by “The categorical variables are shown as n (%), the 
continuous variables as mean (SD)”.  
 
The Table 2 has been modified as follow:  
-the max score corresponds to the maximum assigned score by the nomogram. In this column, we have changed 
the title as “Max assigned score in nomogram”. In addition, the legend was modified as follow: “Maximum 
number for the highest observed value assigned by a nomogram for each predictor”. 
-the range has been replaced by median (IQR) as requested; 
-the Bootstrap Hazard Ratio (BHR) has been added just before its 95% confidence interval. 
 
Table 2: Multivariate Cox model 
 
          
§
Max assigned 
score in   Internal validation 
Parameters   HR 95 % CI p-value nomogram Median (IQR) BHR BCI HR 95 % 
SCA1 
        
Age at baseline (years) 1.01 0.98    1.04 0.53021 6 46 (37  55) 1.003 0.975   1.033 
Dysphagia (yes) 4.52 1.83    11.15 0.00107 17 0 (1    1) 7.029 1.939   41.81 
SARA score 
 
1.26 1.19     1.33 <.0001 100 13.5 (8.5   20.5) 1.288 1.201    1.382 
SCA2 
        
Age at baseline (years) 1.04 1.01    1.08 0.01300 51 47.5 (37   54) 1.045 1.009    1.082 
CAG (number repeats) 1.16 1.03    1.31 0.01580 53 39 (37   41) 1.172 1.028    1.337 
SARA score 
 
1.15 1.10    1.20 <.0001 100 14 (10   19.5) 1.155 1.103    1.210 
SCA3 
        
Age at baseline (years) 1.44 1.20    1.74 0.0001 100 48 (40   56) 1.692 1.179    2.486 
Dystonia (yes) 2.65 1.21    5.53 0.0151 4 0 (0    0) 2.898 1.132    7.341 
SARA score 
 
1.26 1.17    1.35 <.0001 33 14 (10   20.5) 1.295 1.189    1.406 
CAG (number repeats) 1.04 0.89    1.21 0.6501 5 69 (66   72) 1.151 0.867    1.533 
Interaction Age*CAG 0.994 0.991  0.997 <.0001 86 3328 (2850    3776) 0.993 0.988    0.998 
SCA6 
        
Age at baseline (years) 1.02 0.95    1.08 0.6426 14 67 (58   73) 1.018 0.947    1.096 
SARA score   1.17 1.08    1.27 0.0001 100 14 (10.5   19) 1.187 1.080     1.306 
HR: hazard ratio, CI: confidence interval, BHR: bootstrap hazard ratio, BCI: bootstrap confidence interval; 
§
Maximum number for the highest observed value assigned by a nomogram for each predictor. 
 
b. Please supply the figures for your main paper as separate editable files, and please indicate at resubmission 
what programme was used to create them. For more information on our requirements please see: 
http://download.thelancet.com/flatcontentassets/authors/artwork-guidelines.pdf 
Unfortunately, the current versions do not seem to be editable as supplied in Word or PDF format, as I am 
unable to select individual parts of the figure. 
 
We have used a SAS macro to create figure 1 and 2: the %NEWSURV SAS program developed by Jeffrey 
Meyers from Mayo Clinic. The macro is downloadable from the following link: 
http://www.sascommunity.org/wiki/Kaplan-Meier_Survival_Plotting_Macro_%25NEWSURV 
The figures 1 and 2 have been re-uploaded in pdf vectordrawing format and with the modifications requested. 
 
c. in figure 1, could the "Total" column be omitted to avoid overlap with the numbers at risk below the figure? 
 
The “Total” column has been omitted for both Figures. 
 
d. could "+ Censor" be omitted or explained, for both figures? 
 
The “"+ Censor” has been omitted for both Figures. 
 
e. in figure 2, what is meant by "score1cl" etc? 
  
This is the categorized prognostic group variable. This label as modified for "Prognosis group" in Figure 2. 
 
3. Administrative matters 
a. please ensure that we have an ICMJE form (http://www.thelancet.com/pb/assets/raw/Lancet/authors/icmje-
coi-form.pdf) for each author. Apologies if I've missed them - as there are many forms repeated online and it was 
hard to be sure what was and wasn't there - but I couldn't see forms for PG, JI, CaM, LN, MarP, AB, PC, JB, and 
K-JS. 
 
The forms have been re-uploaded as requested. 
 
b. please ensure that all declarations match the ICMJE forms. For example, the form for Dr Schulz includes 
declarations that aren't in the paper - in such cases please either update the paper or supply a new ICMJE form 
that matches the paper. 
 
The modifications have been performed as requested. In addition declarations of Dr Kang have been updated. 
 
c. please supply signed author statement forms  
(http://www.thelancet.com/pb/assets/raw/Lancet/authors/tln-author-signatures.pdf) for all authors. Again I might 
have missed them, but I couldn't see forms for PG and K-JS. 
 
The forms have been re-uploaded as requested. 
 
d. please supply a signed statement to confirm that all authors agree with their contribution as listed in the 
revised paper. Several of the signed author statement forms we do have currently lack the page that lists the 
contributions (eg, MR, ASo, ASu, AA, AF, SB, but there might be others), and we will need to receive formal 
confirmation that these authors agree with their contributions as listed. 
 
The forms have been re-uploaded as requested. 
 
e. please supply a new signed author statement form from Dr Brice, as the current one seems to have no 
signature. 
 
The form has been re-uploaded as requested. 
 f. please supply signed consent from the people named in your acknowledgments section to confirm that they 
agree to be mentioned in this way. 
 
The forms have been uploaded as requested.  
 
g. I could not see a response to our comments on data sharing. As a reminder, we encourage authors to share any 
additional data, preferably translated into English, that would facilitate the replication or further analysis of their 
work—eg, the raw numbers underlying their analysis or the code for any modelling. If authors wish to share 
their supporting data, and have not already made alternative arrangements, a Mendeley DOI can be referred to in 
a section entitled "Data sharing" at the end of the Methods section, ahead of "Role of the funding source". If 
authors have already deposited their data in another repository, or have made other arrangements for data to be 
shared (eg, by means of an adjudication process or contacting the authors), they should use this section to 
elaborate. 
 
The consent obtained from the study participants did not include publishing raw data in a repository. However, 
we are willing and able to share data upon request provided that the objective of the planned analysis is 
compatible with the consent given by the participants. 
 
-------Comments from reviewers---- 
 
Reviewer #5: statistical reviewer 
I would like to thank the authors for addressing my comments. I could not find the information on post-hoc 
statistical power in the manuscript.  
 
This should be be reported in the statistical analysis section  
 
The information on post-hoc statistical power has been added in the statistical analysis section as follows: 
 
Because the backward selection model heavily relies on statistical significance which in turn depends on 
statistical power, we computed a posteriori statistical power to highlight an increase in the risk of death of 2 (HR 
= 2) for any binary variable with a proportion of patient of 50% in each group (para 3, Methods).   
 
and the Results section to support the discussion of the limited statistical power for some analyses. 
 
The information on post-hoc statistical power has been added in the Results section as follows: 
 
A posteriori statistical power to highlight an increase in the risk of death of 2 (HR = 2) for any binary variable 
with a proportion of patient of 50% in each group was 55%, 58%, 53% and 24% for SCA1, 2, 3 and 6 
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Figure 1: Prognostic nomograms to predict the probability of individual overall survival of patients with 
spinocerebellar ataxia type 1, 2, 3, and 6. 
Points are assigned to each risk factor by drawing a line upward from the corresponding value to the ‘Points’ 
line. The total sum point for the three factors is plotted on the ‘Total points’ line. A line is drawn down to read 
the corresponding predictions of the probability of five- and 10-year survival.  
For example, a 50-year-old SCA1 patient (3 points) with dysphagia (17 points) and a SARA score of 20 (50 
points) has 70 points (3 + 17 + 50), placing him in the intermediate group with a probability of five- (blue line) 
and 10-year (red line) survival of 80% and 5%, respectively. 
 
Figure 2: Calibration plots for predicting ataxia patient overall survival at each time point by genotype.  
 
The X-axis shows the nomogram predicted probability of survival. Patients were grouped by quartiles of 
predicted risk. The Y-axis is the actual probability of five- (blue) and 10-year (red) survival estimated by the 
Kaplan-Meier method. The solid line represents the values from the nomograms with their 95% CI. A plot along 
a 45-degree line (dotted line) would indicate a perfect calibration model in which the predicted probabilities are 






Table 1: Univariate Cox model in SCAs of the 28 potential predictors of death 
 
 SCA1 SCA2 SCA3 SCA6 
 HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) 
Gender (male) 0·80 (0·41  1·56) 1·34 (0·71  2·54) 1·42 (0·72  2·80) 1·61 (0·52  4·94) 
Age at onset (years) 0·84 (0·78  0·90) 0·90 (0·86  0·95) 0·89 (0·85  0·94) 0·97 (0·90  1·04) 
Disease duration (years) 1·20 (1·12  1·28) 1·11 (1·05  1·16) 1·12 (1·06  1·18) 1·03 (0·96  1·12) 
Number of CAG repeats  1·13 (1·06  1·19) 1·27 (1·15  1·40) 1·21 (1·08  1·34) 1·11 (0·36  3·42) 
BMI (kg/m
2
) 0·81 (0·74  0·90) 0·94 (0·86  1·04) 0·94 (0·85  1·03) 1·02 (0·88  1·17) 
SARA score 1·23 (1·17  1·29) 1·16 (1·12  1·21) 1·16 (1·12  1·20) 1·17 (1·08  1·27) 
Number of non-ataxia signs  1·60 (1·32  1·95) 1·42 (1·24  1·63) 1·99 (1·62  2·46) 1·22 (0·94  1·58) 
Hyperreflexia (yes) 0·66 (0·34  1·30) 0·74 (0·26  2·10) 1·73 (0·84  3·57) 0·71 (0·15  3·28) 
Areflexia (yes) 2·53 (1·22  5·26) 1·82 (0·86  3·85) 1·28 (0·58  2·82) 0·75 (0·20  2·89) 
Extensar plantar (yes) 2·01 (0·94  4·29) 1·21 (0·60  2·43) 2·78 (1·34  5·77) * 
Spasticity (yes) 0·67 (0·34  1·30) 1·59 (0·61  4·10) 4·14 (1·77  9·67) 2·34 (0·64  8·59) 
Paresis (yes) 2·90 (1·47  5·74) 3·32 (1·60  6·91) 4·36 (2·16  8·80) 3·19 (0·71  14·42) 
Muscle atrophy (yes) 3·96 (2·03  7·73) 6·14 (3·14  12·00) 2·89 (1·41  5·95) 0·45 (0·06  3·49) 
Fasciculations (yes) 3·39 (1·67  6·88) 1·93 (1·00  3·69) 3·04 (1·54  6·02) * 
Myoclonus (yes) 3·22 (1·13  9·17) 2·80 (1·34  5·87) 1·84 (0·43  7·86) * 
Rigidity (yes) 2·83 (0·36  22·05) 5·44 (2·37  12·49) 3·19 (1·36  7·46) 8·83 (2·64  29·55) 
Chorea/dyskenia (yes) 3·01 (1·04  8·73) 3·83 (1·46  10·02) 7·83 (3·57  17·20) 2·54 (0·31  20·80) 
Dystonia (yes) 3·63 (1·73  7·61) 2·31 (1·09  4·90) 4·10 (2·08  8·07) 1·98 (0·25  15·61) 
Resting tremor (yes) 3·08 (1·17  8·07) 1·27 (0·53  3·04) 2·06 (0·49  8·67) 4·38 (0·56  34·19) 
Sensory symptoms (yes) 1·68 (0·74  3·82) 0·63 (0·31  1·26) 1·48 (0·63  3·49) 0·89 (0·29  2·76) 
Urinary dysfunction (yes) 2·01 (1·02  3·96) 1·25 (0·65  2·38) 1·81 (0·87  3·75) 2·99 (0·96  9·29) 
Cognitive impairment (yes) 3·03 (1·520  6·03) 2·63 (1·36  5·08) 1·03 (0·44  2·40) 3·13 (0·93  10·57) 
Brainstem oculomotor signs (yes) 1·63 (0·85  3·14) 1·36 (0·71  2·61) 3·01 (1·40  6·46) 2·32 (0·68  7·90) 
Dysphagia (yes) 4·14 (1·81  9·48) 1·59 (0·82  3·07) 1·93 (0·92  4·06) 0·98 (0·33  2·93) 
Double vision (yes)  1·71 (0·77  3·84) 1·22 (0·58  2·60) 1·39 (0·69  2·81) 1·94 (0·65  5·79) 
§
Any physiotherapy use (yes)  1·85 (0·96  3·57) 1·23(0·65  2·34) 0·79 (0·40  1·56) 0·96 (0·32  2·90) 
PHQ-9 sum score  1·05 (1·00  1·10) 0·99(0·93  1·07) 1·06 (1·02  1·11) 1·05 (0·96  1·14) 
Disease stage (Independent as 
reference)  1 1 1 1 
 Dependent on walking aids 5·36 (2·07  13·83) 2·83 (1·22  6·67) 15·33 (1·99  118·21) 7·911 (0·88  57·73) 
 Dependent on wheelchair 48·0 (16·16  142·70) 10·25 (4·75  22·13) 91·76 (12·0  700·7) 13·64 (1·30  143·0) 
*The model did not converge due to the absence of an event (death) in one of the modalities, HR: hazard ratio, 
CI: confidence interval, bold indicates the significance of a predictor of risk of death (HR not included 1); 
§
















Our proposed cut-off (55, 25 and 20%) 
SCA1 2·7 – 120·4 <48 (64)
§
 48 – 70 (29) >70 (24) 0.905 
SCA2 31·7 – 146·4 <74 (90) 74 – 102 (40) >102 (32) 0.822 
SCA3
₸
 39·9 – 131·7 <79 (77) 79 – 92 (33) >92 (29) 0.891 
SCA6 3·5 – 112·0 <53 (60) 53 – 68 (25) >68 (22) 0.825 
According to tertile (33, 33 and 33%) 
SCA1 2·7 – 120·4 <35 (39) 35 – 56 (39) >56 (39) 0.823 
SCA2 31·7 – 146·4 <62 (53) 62 – 83 (53) >83 (55) 0.781 
SCA3
₸
 39·9 – 131·7 <69 (44) 69 – 84 (44) >84 (46) 0.715 
SCA6 3·5 – 112·0 <42 (35) 42 – 58 (35) >58 (37) 0.726 
Proposed by DR Cox (27, 49.5 and 27%) 
SCA1 2·7 – 120·4 <29 (32) 29 – 45 (57) >45 (28) 0.825 
SCA2 31·7 – 146·4 <59 (44) 59 – 71 (79) >71 (38) 0.774 
SCA3
₸
 39·9 – 131·7 <65 (36) 65 – 91 (66) >91 (32) 0.712 
SCA6 3·5 – 112·0 <39 (29) 39 – 67 (53) >67 (25) * 
₸
Interaction between age and CAG repeat length (age x CAG) was divided by 1,000 in the total score 
computation; *Model did not converged; 
§





Table 3: Discrimination measures and β estimates with their SE from the Cox model 
  
SCA1 SCA2 SCA3 SCA6 
Measures 
 





0·905 0·027 0·822 0·032 0· 891 0·021 0·825 0·054 
β (SE): group 2 versus 1 2·110 0·549 1·233 0·465 1·031 0·461 2·432 1·118 
β (SE): group 3 versus 1 4·614 0·640 2·373 0·425 1·735 0·413 3·411 1·062 
All values are based on scores from the nomograms. The risk groups were: group 1 (Good prognosis), group 2 
(Intermediate prognosis), and group 3 (Poor prognosis). β is the estimate with their SE from the Cox model. 











Table 4: Individual non-ataxia signs characteristics at baseline  
 
    SCA1 SCA 2 SCA 3 SCA 6 
    (n=117) (n=162) (n=139) (n=107) 
Hyperreflexia (n, % yes) 79 (68) 21 (13) 53 (39) 23 (22) 
Areflexia (n, % yes) 21 (18) 104 (65) 78 (57) 24 (23) 
Extensor plantor sign (n, % yes) 54 (51) 45 (31) 57 (42) 2 (2) 
Spasticity (n, % yes) 67 (59) 14 (9) 60 (44) 15 (15) 
Paresis (n, % yes) 27 (23) 23 (15) 34 (25) 6 (6) 
Muscle atrophy (n, % yes) 34 (29)  35 (22) 52 (38) 12 (12) 
Fasciculations (n, % yes) 45 (39) 61 (38) 51 (37) 3 (3) 
Myoclonus (n, % yes) 5 (4) 22 (14) 6 (4) 0 (0) 
Rigidity (n, % yes)  2 (2) 11 (7) 14 (10) 6 (6) 
Chorea/dyskenia (n, % yes) 8 (7) 11 (7) 14 (10) 2 (2) 
Dystonia (n, % yes) 15 (13) 23 (14) 33 (24) 4 (4) 
Resting tremor (n, % yes) 8 (7) 24 (15) 5 (4) 2 (2) 
Sensory symptoms (n, % yes) 69 (62) 106 (69) 83 (65) 49 (47) 
Urinary dysfunction (n, % yes) 41 (35) 64 (40) 63 (46)  32 (30) 
Cognitive impairment (n, % yes)  25 (22) 41 (26) 26 (19) 10 (9) 
Brainstem oculomotor signs (n, % yes) 44 (38) 58 (36) 72 (53) 18 (17) 
Dysphagia (n, % yes) 70 (60) 85 (53)  83 (60) 58 (54) 

















Table 5: Predicted probability and actual observed five- and 10-year survival 
    Time prediction  
  
5-year survival prediction 10-year survival prediction 
Genotype 
§
Groups Predicted Observed Predicted Observed 
SCA1 
     
 
1 0.306 0.302 0.000 0.000 
 
2 0.885 0.881 0.327 0.315 
 
3 0.980 1.000 0.831 0.867 
 
4 0.999 1.000 0.952 0.950 
SCA2 
     
 
1 0.640 0.630 0.351 0.335 
 
2 0.937 0.943 0.828 0.823 
 
3 0.909 0.918 0.816 0.832 
 
4 0.995 1.000 0.961 0.971 
SCA3 
     
 
1 0.584 0.577 0.167 0.144 
 
2 0.912 0.926 0.758 0.773 
 
3 0.991 1.000 0.933 0.966 
 
4 0.999 1.000 0.997 1.000 
SCA6 
     
 
1 0.909 0.910 0.700 0.682 
 
2 0.999 1.000 0.807 0.815 
 
3 0.999 1.000 0.934 0.955 
  4 0.998 1.000 0.990 1.000 
§
Participants for each genotype were grouped in quartiles based on the risk score from the respective multivariate 
model. 
In each genotype, the predicted probability of five- and 10-year survival was very close to the actual observed 
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Table 6: List of the 17 participant centers. 
 
N° Centers EUROSCA study group 
1 London  Arron Cook, Paola Giunti, Robyn Labrum 
2 Paris  Alexandra Durr, Alexis Brice, Perrine Charles, Cecilia Marelli 
3 Milan Caterina Mariotti, Lorenzo Nanetti, Marta Panzeri 
4 Warsaw Maria Rakowicz, Anna Sobanska, Anna Sulek 
5 Bonn Heike Jacobi, Thomas Klockgether, Tanja Schmitz-Hübsch 
6 Tubingen Peter Bauer, Ludger Schöls, Holger Hengel 
7 Naples Alessandro Filla, Antonella Antenora 
8 Pécs Bela Melegh 
9 Santander Jon Infante, José Berciano 
10 Nijmegen Bart P. van de Warrenburg 
11 Essen Dagmar Timmann 
12 Bochum  
13 Innsbruck Sylvia Boesch 
14 Frankfurt Kang Jun-Suk 
15 Bruxelles Massimo Pandolfo 
16 GO1  
17 Aachen Jörg B. Schulz 
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TRIPOD Checklist: Prediction Model Development 
 
Section/Topic Item Checklist Item Page 
Title and abstract 
Title 1 
Identify the study as developing and/or validating a multivariable prediction model, 






Provide a summary of objectives, study design, setting, participants, sample size, 






Explain the medical context (including whether diagnostic or prognostic) and 
rationale for developing or validating the multivariable prediction model, including 






Specify the objectives, including whether the study describes the development or 






Source of data 
4a 
Describe the study design or source of data (e.g., randomized trial, cohort, or 






Specify the key study dates, including start of accrual; end of accrual; and, if 







Specify key elements of the study setting (e.g., primary care, secondary care, 










5c Give details of treatments received, if relevant.   
Outcome 
6a 
Clearly define the outcome that is predicted by the prediction model, including how 





6b Report any actions to blind assessment of the outcome to be predicted.   
Predictors 
7a 
Clearly define all predictors used in developing or validating the multivariable 






Report any actions to blind assessment of predictors for the outcome and other 
predictors.  
 
Sample size 8 Explain how the study size was arrived at.  
Missing data 9 
Describe how missing data were handled (e.g., complete-case analysis, single 














Specify type of model, all model-building procedures (including any predictor 




Specify all measures used to assess model performance and, if relevant, to 













Describe the flow of participants through the study, including the number of 
participants with and without the outcome and, if applicable, a summary of the 






Describe the characteristics of the participants (basic demographics, clinical 
features, available predictors), including the number of participants with missing 



















Present the full prediction model to allow predictions for individuals (i.e., all 





15b Explain how to the use the prediction model. 











Discuss any limitations of the study (such as nonrepresentative sample, few events 









19b Give an overall interpretation of the results, considering objectives, limitations, and 

















Provide information about the availability of supplementary resources, such as study 
protocol, Web calculator, and data sets.  
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